Merck and Eli Lilly

Paper Summary:

This paper takes a close look at the market value of two of America's largest pharmaceutical companies, Merck and Eli Lilly. It examines both companies' profiles, profit margins, revenue, and future market predictions. The paper explores the different drugs offered by both companies and explains why information about these drugs is so important for investment purposes. Finally, the paper shows why Eli Lilly should be chosen over Merck as a prospective investment.

From the Paper:

"In many respects, Cialis represents Eli Lilly's performance in the markets: people are seeing Lilly as a vibrant company with a pipeline that is well-stocked with good ideas that will sustain its performance over the next several years. Much relies on an investor's particular discipline and his or her faith in the efficient market hypothesis. The growth investor will prefer Eli Lilly: here is a company that made itself with Prozac, which it targeted to depressed young adults. It is sustaining its profits with a drug for ADHD and a drug for hyperactivity, which are also drugs for a younger market. This type of drug will survive attempts by the federal government to push the elderly to purchase generics with money provided by a prescription drug program."

More papers on Merck and Eli Lilly:

• Essay # 61220 : "Pfizer, Inc. and the Pharmaceutical Industry"
• Analytical Essay # 27757 : "Merck and Pfizer Inc."
• Analytical Essay # 61299 : "Pfizer"

APA Citation:

MLA Citation: